ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 40 citations in OpenAlex.
- HSP90 shields ROC1/RBX1 from proteasomal degradation by CHIP E3 ubiquitin ligase to promote lung adenocarcinoma.Signal transduction and targeted therapy · 2026Article
- YTHDF3 Promotes the Progression of Gastric Cancer by Activating the Wnt/β-Catenin Signaling Pathway via Targeting NEK7.Journal of gastroenterology and hepatology · 2026Article
- CHIP protects rheumatoid arthritis progression by targeting TRAF6 in arthritis animal models.Journal of orthopaedic translation · 2026Article
- AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma.Cell death & disease · 2026Article
- RNA modification-mediated multidimensional crosstalk: a novel perspective on gene expression regulation.Genome biology · 2026Review
- TargetingJournal of Zhejiang University. Science. B · 2026Article
- Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal Tumors.Journal of clinical medicine · 2026Article
- USP1 driven mitotic dysregulation and PLK1 stabilization confer Lenvatinib resistance in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Mechanisms and therapeutic potential of YTHDF readers: Linking epitranscriptomics to cancer.Journal of pharmaceutical analysis · 2026Review
- A bibliometric analysis of research trends and emerging frontiers in heat shock proteins and hepatocellular carcinoma from 2015 to 2025.Discover oncology · 2026Article
- Bidirectional regulation of the ubiquitin-RNA modification axis in cancer.Frontiers in oncology · 2026Review
- Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential.Frontiers in molecular biosciences · 2026Review
- METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.Oncogene · 2025Article
- CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.Breast cancer research : BCR · 2025Article
- Cordycepin Targets HRD1 to Promote Cancer Cell PD-L1 Ubiquitin-Proteasome Degradation and Increase Antitumor Immunity.MedComm · 2025Article
- YTHDF1 regulates YTHDF2 stability via m6A-dependent mechanisms in hepatocellular carcinoma: insights fromJournal of gastrointestinal oncology · 2025Article
- PDLIM4 drives gastric cancer malignant progression and cisplatin resistance by inhibiting HSP70 ubiquitination and degradation via competitive interaction with STUB1.Journal of nanobiotechnology · 2025Article
- Doublecortin-like kinase 1, regulated by STIP1 homology and U-box containing protein 1 or Sp1 transcription factor, affects the malignant behaviors and drug sensitivity in adriamycin-resistant breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer.Oncology letters · 2025Article
- O-GlcNAcylation of YTHDF2 antagonizes ERK-dependent phosphorylation and inhibits lung carcinoma.Fundamental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Yuning LiaoAffiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou, 510095, China.
Yuan LiuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Cuifu YuShenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei, 516600, China.
Qiucheng LeiDepartment of Hepatopancreatic Surgery, The First People's Hospital of Foshan, Foshan, 528000, China.
Ji ChengGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Weiyao KongGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yuanhui YuKingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China.
Xuefen ZhuangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Wenshuang SunGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Shusha YinGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Gengxi CaiDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, 528000, China.
Hongbiao HuangAffiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou, 510095, China.ORCID 0000-0002-9873-0559
Guangzhou Medical University · CNFirst People's Hospital of Foshan · CNGuangzhou Medical University Cancer Hospital · CNKingmed Diagnostics · CNSun Yat-sen University · CN
Funding
Cultivation Program of National Natural Science Foundation for Distinguished Young Scholars of Guangzhou Medical University JP2022002Guangzhou Medical University JCXKJS2022A06National Natural Science Foundation of China 82002481National Natural Science Foundation of China 82072810Science and technology innovation project of Foshan 2220001003854Science and technology innovation project of Foshan 2220001004847scientific research in Guangzhou Medical UniversityUniversities in Guangdong Province 2022KCXTD021
Abstract
YTH domain family 2 (YTHDF2) is the first identified N6-methyladenosine (m
Indexed as
Carcinoma, HepatocellularHSP90 Heat-Shock ProteinsLiver NeoplasmsHumansRNA-Binding ProteinsSorafenibUbiquitinationUbiquitin-Protein LigasesUp-RegulationHSP90 Heat-Shock ProteinsRNA-Binding ProteinsSorafenibSTUB1 protein, humanUbiquitin-Protein LigasesYTHDF2 protein, humanhepatocellular carcinomaHSP90βSTUB1ubiquitinationYTHDF2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.